{
    "root": "35b5afa9-33f7-60bc-e063-6394a90a71db",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eszopiclone",
    "value": "20250522",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "ESZOPICLONE",
            "code": "UZX80K71OE"
        }
    ],
    "indications": "Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance.\n                  The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).",
    "contraindications": "Use the lowest effective dose for the patient.",
    "warningsAndPrecautions": "Eszopiclone Tablets, USP, 3 mg are round, dark blue, film-coated, and identified with debossed markings of ‘384’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-354-30 bottle of 30 tablets (relabeled from NDC 68462-384-30)\n                         NDC 76420-354-60 bottle of 60 tablets (repackaged from NDC 68462-384-XX)\n                         NDC 76420-354-90 bottle of 90 tablets (repackaged from NDC 68462-384-XX)\n                         NDC 76420-354-01 bottle of 100 tablets (relabeled from NDC 68462-384-01)\n                         NDC 76420-354-10 bottle of 1000 tablets (relabeled from NDC 68462-384-10)\n                  Eszopiclone Tablets, USP, 2 mg are round, white to off-white, film-coated, and identified with debossed markings of ‘383’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-353-30 bottle of 30 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-60 bottle of 60 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-90 bottle of 90 tablets (repackaged from NDC 68462-383-XX)\n                         NDC 76420-353-01 bottle of 100 tablets (relabeled from NDC 68462-383-01)\n                         NDC 76420-353-10 bottle of 1000 tablets (relabeled from NDC 68462-383-10)\n                  Eszopiclone Tablets, USP, 1 mg are round, light blue, film-coated, and identified with debossed markings of ‘382’ on one side, and ‘G’ on the other side and are supplied as:\n                         NDC 76420-352-30 bottle of 30 tablets (relabeled from NDC 68462-382-30)\n                         NDC 76420-352-60 bottle of 60 tablets (repackaged from NDC 68462-382-XX)\n                         NDC 76420-352-90 bottle of 90 tablets (repackaged from NDC 68462-382-XX)\n                         NDC 76420-352-01 bottle of 100 tablets (relabeled from NDC 68462-382-01)\n                         NDC 76420-352-10 bottle of 1000 tablets (relabeled from NDC 68462-382-10)\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°F to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Eszopiclone tablets are contraindicated in patients who have experienced complex sleep behaviors after taking eszopiclone tablets\n  \n    [see Warnings and Precautions (\n                           \n                              5.1)]\n  \n    .\n \n   \n                     \n                     Eszopiclone tablets are contraindicated in patients with known hypersensitivity to eszopiclone. Hypersensitivity reactions include anaphylaxis and angioedema\n  \n   [see Warnings and Precautions (\n   \n    5.3)]."
}